Companies
Gene-Editing Companies by Founding Year
The sector in chronological order, which shows how tightly the founding wave clusters around 2013.
यह सूची कैसे बनती है
Sorting companies by when they were founded shows something striking: a cluster in 2013, immediately after CRISPR was shown to work in human cells, and then successive waves as each new technique arrived, with base editing companies around 2017 and prime editing from 2019.
| # | प्रविष्टि | श्रेणी | Founded | स्थिति |
|---|---|---|---|---|
| 1 | Eli Lilly and Company A major pharmaceutical company that entered gene editing by acquisition, buying Verve… | Large pharmaceutical | 1876 | Phase II |
| 2 | Vertex Pharmaceuticals The established biotechnology company that partnered on, and commercialises, the first… | Large biotechnology | 1989 | Approved |
| 3 | Sangamo Therapeutics The company that took gene editing into humans first, years before CRISPR existed as a… | Zinc finger platform | 1995 | Phase III |
| 4 | Caribou Biosciences Co-founded by Jennifer Doudna, using hybrid RNA-DNA guides intended to make editing… | Cell therapy | 2011 | Phase I |
| 5 | CRISPR Therapeutics Co-founded by Emmanuelle Charpentier, and the company behind the first approved CRISPR… | CRISPR-Cas9 platform | 2013 | Approved |
| 6 | Editas Medicine One of the first CRISPR companies, which discontinued its cell-therapy and eye programmes… | In vivo editing | 2013 | Preclinical |
| 7 | Intellia Therapeutics Co-founded by Jennifer Doudna, and the company that first delivered CRISPR into a human… | In vivo CRISPR platform | 2014 | Phase III |
| 8 | Arbor Biotechnologies Co-founded by Feng Zhang and David Scott to discover new editing enzymes from nature at… | Novel editors | 2016 | Phase I |
| 9 | Beam Therapeutics Founded by David Liu and colleagues to commercialise base editing: precision changes to… | Base editing platform | 2017 | Phase III |
| 10 | Mammoth Biosciences Co-founded by Jennifer Doudna around ultra-compact CRISPR proteins small enough to fit… | Miniature editors and diagnostics | 2017 | Preclinical |
| 11 | Sana Biotechnology Engineering transplanted cells to be invisible to the immune system, so they can be given… | Cell engineering | 2018 | Phase I |
| 12 | Scribe Therapeutics Co-founded by Jennifer Doudna to engineer CRISPR enzymes from scratch rather than use the… | Engineered editors | 2018 | Preclinical |
| 13 | Tessera Therapeutics Developing 'gene writing': mobile genetic elements repurposed to insert whole sequences… | Gene writing | 2018 | Preclinical |
| 14 | Verve Therapeutics Built to turn heart disease into a one-time treatment, and acquired by Eli Lilly in 2025… | In vivo base editing | 2018 | Phase II |
| 15 | Prime Medicine Founded to commercialise prime editing, and the company behind the first published… | Prime editing platform | 2019 | Phase I/II |
| 16 | Tune Therapeutics Turning genes up and down without changing sequence: epigenetic editing taken into early… | Epigenetic editing | 2021 | Phase I |
यह सूची आपको क्या नहीं बतातीFounding dates are as reported by the companies. This is not a complete census of the sector.